Roger Barker is Professor of Clinical Neuroscience and Honorary Consultant in Neurology at the University of Cambridge and at Addenbrooke’s Hospital. He trained at Oxford and London and has been in his current position since 2000, after completing an MRC Clinician Scientist Fellowship.
Roger combines basic research looking at novel therapies to treat chronic neurodegenerative disorders of the brain with clinically-based work aimed at better defining such disorders. He is the co-ordinator of the TRANSEURO project looking at fetal cell grafting in patients with early Parkinson’s Disease and is part of the GFORCE PD initiative as well as Director of the International Society for Stem Cell Research.
The goal of the iSAB is to steer and challenge the Hub in its development and delivery of our scientific and translational objectives. The PSEC Advisory Board consist of the following members:
Prof Jack Price
Kings College London
Until recently, Jack Price was Head of the Division of Advanced Therapies, at the UK National Institute for Biological Standards and Control and Director of the UK stem Cell Bank. He is Professor of Developmental Neurobiology and former Head of the Cells & Behaviour Unit at the Institute of Psychiatry Psychology & Neuroscience, King’s College London. Prof Price studied at UCL and MIT, before leading a research group at the National Institute for Medical Research, Mill Hill. He was a Research Director at SmithKline Beecham Pharmaceuticals until joining King’s College London in 1998. Previously, he was a consultant to ReNeuron Ltd from 1998 until taking up his current post a NIBSC.
Prof Price’s specific interest is the commercial and clinical translation of gene and cell therapies from an academic, commercial, and regulatory perspective.
Jacqueline Barry, PhD.,
Chief Clinical Officer and an Executive Director
The Cell and Gene Therapy Catapult.
Jacqueline Barry is the Chief Clinical Officer, responsible for Clinical Translation and Delivery activities and an Executive Director of the Cell and Gene Therapy Catapult. She has extensive experience in the development of advanced therapy medicinal products and leads a multi-disciplinary team of Nonclinical, Regulatory, Clinical Operations and Programme Management specialists. She also leads the coordination of the UK Advanced Therapy Treatment Centre Network and is a Director of the Global Alliance for iPSC Therapies.
She feels passionately about making advanced therapies available for patients and works closely with the MHRA and the NHS on the development of the ecosystems to support the adoption of these therapies.
Prior her time at Cell and Gene Therapy Catapult, Jacqueline worked at the Scottish National Blood Transfusion Service where amongst other activities she designed the regulatory strategy for the Cellular Therapies for the Blood Transfusion Service and acted as Qualified Person for their release. She has a PhD from the University of Aberdeen and did post-doctoral research in neurophysiology at the University of Edinburgh.
Dr Andreas Bosio
Head of Molecular Technologies and Stem Cell Therapy
Miltenyi Biotec
Andreas Bosio received a degree in Chemistry and a PhD in Biochemistry at the University of Cologne, Germany. He was part of the founding team and CSO of MEMOREC Stoffel GmbH. In 2003, he joined Miltenyi Biotec and is now Head of the R&D department Molecular Technologies and Stem Cell Therapy and brings a wealth of industrial expertise to our scientific advisory board.
Julian Braybrook, BSc(Hons), PhD(Cantab), Hon DSc(Kingston), CChemFRSC
UK Government Chemist
Director of Measurement Science & Partnerships at the National Measurement Laboratory, LGC
Visiting Professor of Biometrology, Loughborough University
Julian Braybrook has over 25 years’ experience in delivering successful national & European measurement research innovation for public & private sector accounts. He was responsible for the science & partnership strategy for the National Measurement Laboratory (NML) & Designated Institute for chemical & bio-metrology at LGC. As the UK Government Chemist, he provides the statutory referee role in case of technical dispute & advises government on chemical & bio-measurement for standards & legislation.
Julian advised the Commission on the development of their innovation & commercialisation portfolio of medical material-funded research activities spanning several European Framework Programmes.
Furthermore, he has held several national, European & international positions, informing standards generation & application in regenerative medicine & consumer safety products. Currently Chair of BSI Biotechnology standards committee (BTI/1) & Lead for UK delegation to ISO TC/276. Active member of BIA Advisory Committees for cell & gene therapy, & science & innovation. Industrial member of IOM3 Biomedical Materials Applications Division.
Kevin Eggan, Ph.D.,
Professor in the Department of Stem Cell and Regenerative Biology at Harvard University,
Director of Stem Cell Biology for the Stanley Center for Psychiatric Research at the Broad Institute, and
An Institute Member of the Broad Institute of MIT and Harvard.
Kevin Eggan completed his B.S. in microbiology at the University of Illinois in 1996. A two-year predoctoral internship at Amgen at the National Institutes of Health in Bethesda solidified his desire to pursue a career in academic research. He enrolled at the graduate school of Massachusetts Institute of Technology in 1998 shortly after the cloning of Dolly the Sheep was reported. During his Ph.D. training, he actively pursued projects focused on cloning, stem cells and reprogramming after nuclear transfer under the guidance of genetics pioneer, Dr. Rudolf Jaenisch. He stayed in Dr. Jaenisch’s lab after his graduation for a one-year postdoc training in 2002. During that time, he conducted a collaborative study with Dr. Richard Axel, a Nobel Prize winner at the Howard Hughes Medical Institute. In 2003, he moved to Harvard University as a junior fellow and then became an assistant professor of Molecular & Cellular Biology at the Stem Cell Institute in 2005. In 2009, he was selected as one of 50 Howard Hughes Medical Institute Early Career Scientists receiving six years of dedicated support to conduct transformative research. Dr. Eggan was promoted to Professor in the Department of Stem Cell and Regenerative Biology in 2012.
The success of Dr. Eggan’s laboratory in the study of motor neuron disease has led to his appointment as the Director of the Stem Cell Program at the Stanley Center for Psychiatric Research at the Broad Institute. In this role he is leading a group of scientists to expand the platform to increase reproducibility of stem cell and reprogramming technologies, with the ultimate goal of improving understanding and treatment of psychiatric diseases.
Dr Susanne Sattler
National Heart and Lung Institute at Imperial College, London
Susanne Sattler leads the cardio-immunology group at the National Heart and Lung Institute at Imperial College London, UK. She has extensive research experience in cardiac immunology and regenerative biology and has contributed a significant body of research on the role of a persistent inflammation-autoimmunity loop in tissue immunopathology hampering regenerative efforts.
Susanne obtained her PhD in 2009 from the University of Vienna, Austria. Her PhD project on immunological properties of endothelial cells sparked her interest in the mutual cross talk between the immune and the cardiovascular system. She joined Imperial College London in 2009 as a postdoctoral research associate in the Centre of Complement and Inflammation Research (CCIR). There she developed a keen interest in the regulatory control of immune responses as well as autoimmunity as an inevitable consequence of lacking or aberrant regulatory processes. In 2012, Susanne joined the National Heart and Lung Institute (NHLI) as a member of the Cardiac Regeneration group led by Prof. Nadia Rosenthal. Susanne was promoted to independent Research Fellow in 2017 and now leads the NHLI cardio-immunology team investigating the crosstalk between the adaptive immune system and the heart and how immunomodulation may improve regeneration.
Dr Beata Surmacz-Cordle
Analytical Development Manager, Cell & Gene Therapy Platform CMC, GSK
Beata Surmacz-Cordle received her PhD from Imperial College in London working in the laboratory of Meng Li. She applied developmental biology knowledge to improve differentiation of hESCs to dopaminergic neurons for treatment of Parkinson’s disease. Following her PhD, Beata moved to Pfizer’s Reg Med Unit in Cambridge as a Postdoctoral Fellow, working mainly on CMC process and analytical development for a cell therapy product for Age Related Macular Degeneration (hPSC to RPE cells). This work was performed in close collaboration with Pete Coffey. In addition, Beata also lead work developing drug screening platforms using hPSCs derived sensory neurons and neural stem cells.
After Pfizer, Beata moved to the Cell and Gene Therapy Catapult in London and was given the opportunity to lead analytical development efforts on over 10 different cell and gene therapy products from discovery stage to Phase 2, including GxP. She provided strategic leadership for the Analytics Programme addressing industry wide analytical challenges for ATMPs. In March 2020, she moved to GSK, to lead CMC development, from phase 1 to pivotal, across a portfolio of immuno-oncology cell and gene therapy products.
Dr Steven Howe
Head, Cell and Gene Therapy Process Research, GSK
Professor Paul Fairchild
Sir William Dunn School of Pathology and Trinity College, Oxford
